Efficacy of DZ1462, a Novel Sodium-phosphate Transporter Inhibitor, on 5/6 Nephrectomy-induced Hyperphosphatemia Model Rats
Objective To study the efficacy of DZ1462, a novel sodium-phosphate transporter inhibitor, on rat hyperphosphatemia models established by 5/6 nephrectomy.Methods Totally 156 rats were randomly selected into four groups. Rats fed a normal diet were control group, named as group Ⅰ (n=6); rats fed a no...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Laboratory Animal and Comparative Medicine
2022-06-01
|
| Series: | Shiyan dongwu yu bijiao yixue |
| Subjects: | |
| Online Access: | https://www.slarc.org.cn/dwyx/CN/10.12300/j.issn.1674-5817.2021.138 |
| _version_ | 1811215506263244800 |
|---|---|
| author | LU Xiao ZHANG Lin JI Hui JIANG Shanxiang |
| author_facet | LU Xiao ZHANG Lin JI Hui JIANG Shanxiang |
| author_sort | LU Xiao |
| collection | DOAJ |
| description | Objective To study the efficacy of DZ1462, a novel sodium-phosphate transporter inhibitor, on rat hyperphosphatemia models established by 5/6 nephrectomy.Methods Totally 156 rats were randomly selected into four groups. Rats fed a normal diet were control group, named as group Ⅰ (n=6); rats fed a normal diet after 5/6 nephrectomy were named as group Ⅱ (n=60); rats fed a high phosphate diet after 5/6 nephrectomy were named as group Ⅲ (n=60); rats fed a high phosphate diet after sham surgery were named as group Ⅳ (n=30). The molding cycle was 10 weeks. Serum Pi was detected and the number of animal deaths was recorded every two weeks. Hematoxylin-eosin (HE) staining was performed to observe the change in kidney pathology, and to screen animal models with high phosphorus blood syndrome. Totally 18 model rats that met the inclusion criteria (all of group Ⅲ) were selected and randomly assigned to three groups: the model control group recorded as the G2 group; the DZ1462 administration group (30 mg/kg, tid, 21 d) recorded as the G3 group; the Sevelamer administration group (250 mg/kg, tid, 21 d) recorded as the G4 group. In addition, the normal control group was set as the G1 group. Serum phosphate levels were measured using a kit.Results In the 8th and 10th weeks, compared to group Ⅰ, serum phosphorus in group Ⅲ showed a significant difference (P < 0.01). The kidneys in group Ⅲ had obvious glomerular sclerosis, renal tubular atrophy, degeneration, interstitial inflammation, fibrosis, and calcification. Similarly to chronic kidney disease accompanied by hyperphosphatemia, the animal model was established successfully. At each time point, the serum phosphorus inhibition rate of the G3 group was significantly higher than that of the G4 group (P < 0.05).Conclusion DZ1462, as a novel small-molecule inhibitor of intestinal sodium and phosphorus transporter, can effectively inhibit intestinal phosphorus ion absorption in rat hyperphosphatemia model, and is expected to become a potential drug for the clinical treatment of hyperphosphatemia. |
| first_indexed | 2024-04-12T06:22:37Z |
| format | Article |
| id | doaj.art-6c87d65ef3804a9588118998890e160a |
| institution | Directory Open Access Journal |
| issn | 1674-5817 |
| language | zho |
| last_indexed | 2024-04-12T06:22:37Z |
| publishDate | 2022-06-01 |
| publisher | Editorial Office of Laboratory Animal and Comparative Medicine |
| record_format | Article |
| series | Shiyan dongwu yu bijiao yixue |
| spelling | doaj.art-6c87d65ef3804a9588118998890e160a2022-12-22T03:44:15ZzhoEditorial Office of Laboratory Animal and Comparative MedicineShiyan dongwu yu bijiao yixue1674-58172022-06-0142318719310.12300/j.issn.1674-5817.2021.1381674-5817（2022）03-0187-07Efficacy of DZ1462, a Novel Sodium-phosphate Transporter Inhibitor, on 5/6 Nephrectomy-induced Hyperphosphatemia Model RatsLU Xiao0ZHANG Lin1JI Hui2JIANG Shanxiang3College of Veterinary Medicine, Nanjing Agriculture University, Nanjing 210095, ChinaDizal Pharmaceuticals Co. Ltd., Shanghai 201203, ChinaCollege of Veterinary Medicine, Nanjing Agriculture University, Nanjing 210095, ChinaCollege of Veterinary Medicine, Nanjing Agriculture University, Nanjing 210095, ChinaObjective To study the efficacy of DZ1462, a novel sodium-phosphate transporter inhibitor, on rat hyperphosphatemia models established by 5/6 nephrectomy.Methods Totally 156 rats were randomly selected into four groups. Rats fed a normal diet were control group, named as group Ⅰ (n=6); rats fed a normal diet after 5/6 nephrectomy were named as group Ⅱ (n=60); rats fed a high phosphate diet after 5/6 nephrectomy were named as group Ⅲ (n=60); rats fed a high phosphate diet after sham surgery were named as group Ⅳ (n=30). The molding cycle was 10 weeks. Serum Pi was detected and the number of animal deaths was recorded every two weeks. Hematoxylin-eosin (HE) staining was performed to observe the change in kidney pathology, and to screen animal models with high phosphorus blood syndrome. Totally 18 model rats that met the inclusion criteria (all of group Ⅲ) were selected and randomly assigned to three groups: the model control group recorded as the G2 group; the DZ1462 administration group (30 mg/kg, tid, 21 d) recorded as the G3 group; the Sevelamer administration group (250 mg/kg, tid, 21 d) recorded as the G4 group. In addition, the normal control group was set as the G1 group. Serum phosphate levels were measured using a kit.Results In the 8th and 10th weeks, compared to group Ⅰ, serum phosphorus in group Ⅲ showed a significant difference (P < 0.01). The kidneys in group Ⅲ had obvious glomerular sclerosis, renal tubular atrophy, degeneration, interstitial inflammation, fibrosis, and calcification. Similarly to chronic kidney disease accompanied by hyperphosphatemia, the animal model was established successfully. At each time point, the serum phosphorus inhibition rate of the G3 group was significantly higher than that of the G4 group (P < 0.05).Conclusion DZ1462, as a novel small-molecule inhibitor of intestinal sodium and phosphorus transporter, can effectively inhibit intestinal phosphorus ion absorption in rat hyperphosphatemia model, and is expected to become a potential drug for the clinical treatment of hyperphosphatemia.https://www.slarc.org.cn/dwyx/CN/10.12300/j.issn.1674-5817.2021.1385/6 nephrectomyhyperphosphatemiasodium-phosphate transporter inhibitorsdz1462rats |
| spellingShingle | LU Xiao ZHANG Lin JI Hui JIANG Shanxiang Efficacy of DZ1462, a Novel Sodium-phosphate Transporter Inhibitor, on 5/6 Nephrectomy-induced Hyperphosphatemia Model Rats Shiyan dongwu yu bijiao yixue 5/6 nephrectomy hyperphosphatemia sodium-phosphate transporter inhibitors dz1462 rats |
| title | Efficacy of DZ1462, a Novel Sodium-phosphate Transporter Inhibitor, on 5/6 Nephrectomy-induced Hyperphosphatemia Model Rats |
| title_full | Efficacy of DZ1462, a Novel Sodium-phosphate Transporter Inhibitor, on 5/6 Nephrectomy-induced Hyperphosphatemia Model Rats |
| title_fullStr | Efficacy of DZ1462, a Novel Sodium-phosphate Transporter Inhibitor, on 5/6 Nephrectomy-induced Hyperphosphatemia Model Rats |
| title_full_unstemmed | Efficacy of DZ1462, a Novel Sodium-phosphate Transporter Inhibitor, on 5/6 Nephrectomy-induced Hyperphosphatemia Model Rats |
| title_short | Efficacy of DZ1462, a Novel Sodium-phosphate Transporter Inhibitor, on 5/6 Nephrectomy-induced Hyperphosphatemia Model Rats |
| title_sort | efficacy of dz1462 a novel sodium phosphate transporter inhibitor on 5 6 nephrectomy induced hyperphosphatemia model rats |
| topic | 5/6 nephrectomy hyperphosphatemia sodium-phosphate transporter inhibitors dz1462 rats |
| url | https://www.slarc.org.cn/dwyx/CN/10.12300/j.issn.1674-5817.2021.138 |
| work_keys_str_mv | AT luxiao efficacyofdz1462anovelsodiumphosphatetransporterinhibitoron56nephrectomyinducedhyperphosphatemiamodelrats AT zhanglin efficacyofdz1462anovelsodiumphosphatetransporterinhibitoron56nephrectomyinducedhyperphosphatemiamodelrats AT jihui efficacyofdz1462anovelsodiumphosphatetransporterinhibitoron56nephrectomyinducedhyperphosphatemiamodelrats AT jiangshanxiang efficacyofdz1462anovelsodiumphosphatetransporterinhibitoron56nephrectomyinducedhyperphosphatemiamodelrats |